GRACEcast Bladder Cancer Video

By cancerGRACE - H. Jack West, MDMedicine Education

GRACEcast Bladder Cancer Video episodes

February 27, 2013 Dr. Bob Doebele: Will We Be Able to Use Molecular Markers and Apply Targeted Therapies to Broader Lung Cancer Subtypes in the Near Future?
Dr. Bob Doebele from the University of Colorado offers his perspective on whether targeted therapies will be able to applied to broader populations of patients with advanced NSCLC than those primarily with minimal smoking histories and an adenocarcinoma.
2 min
February 27, 2013 Dr. Monty Pal: How Do We Work Up a Kidney Mass That May Be Cancer?
Dr. Sumanta (Monty) Pal of City of Hope Cancer Center in Duarte, CA reviews a recommended approach to the workup of a kidney mass suspected to be a cancer.
2 min
February 25, 2013 Drs. Ross Camidge and Corey Langer: Who Do You Recommend Repeat Biopsy for if There Isn't Enough Tissue for Molecular Testing?
Drs. Ross Camidge and Corey Langer discuss which patients with advanced NSCLC they would recommend should have a repeat biopsy if their initial tissue sample doesn't have sufficient tissue for molecular testing.
2 min
February 25, 2013 Dr. Sarah Goldberg: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
Dr. Sarah Goldberg reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.
3 min
February 25, 2013 Dr. Karen Kelly: What Molecular Markers Do You Routinely Send for in Your Patients with Advanced Non-Small Cell Lung Cancer?
Dr. Karen Kelly describes her thought process on which molecular markers are those clearly indicated for testing in patients with advanced NSCLC, as well as whether smoking status factors into her approach.
3 min
February 25, 2013 Dr. Heather Wakelee: Do You Use Molecular Marker Information for Management of Earlier Stage Non-Small Cell Lung Cancer?
Dr. Heather Wakelee from Stanford University discusses the open question of whether patients with resectable or locally advanced NSCLC should have testing for molecular markers, as well as how we might use this information in clinical practice.
2 min
February 23, 2013 Dr. Greg Riely: How Should We Approach Acquired Resistance to Targeted Therapies in Advanced NSCLC?
Dr. Greg Riely from Memorial Sloan-Kettering reviews strategies for managing acquired resistance to EGFR inhibitors and other targeted therapies in advanced non-small cell lung cancer.
8 min
February 23, 2013 Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?
Dr. David Spigel, Sarah Cannon Cancer Center, offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.
4 min
February 22, 2013 Dr. Lecia Sequist on Molecular Marker Testing in Advanced NSCLC in 2013: What, Who, and When?
Dr. Lecia Sequist describes the state of the art and her view of current best practices on molecular testing for advanced non-small cell lung cancer.
6 min
February 22, 2013 What is an Inherited T790M EGFR Mutation, and What Does It Mean?
Dr. Geoffrey Oxnard describes the new finding of individuals with an inherited T790M mutation in the EGFR gene, the unclear significance of it, and a study being conducted to learn more about it.
4 min

About GRACEcast Bladder Cancer Video

From the publisher's feed

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to…